Systemic Inflammation in Preclinical Ulcerative Colitis

Gastroenterology. 2021 Nov;161(5):1526-1539.e9. doi: 10.1053/j.gastro.2021.07.026. Epub 2021 Jul 21.

Abstract

Background & aims: Preclinical ulcerative colitis is poorly defined. We aimed to characterize the preclinical systemic inflammation in ulcerative colitis, using a comprehensive set of proteins.

Methods: We obtained plasma samples biobanked from individuals who developed ulcerative colitis later in life (n = 72) and matched healthy controls (n = 140) within a population-based screening cohort. We measured 92 proteins related to inflammation using a proximity extension assay. The biologic relevance of these findings was validated in an inception cohort of patients with ulcerative colitis (n = 101) and healthy controls (n = 50). To examine the influence of genetic and environmental factors on these markers, a cohort of healthy twin siblings of patients with ulcerative colitis (n = 41) and matched healthy controls (n = 37) were explored.

Results: Six proteins (MMP10, CXCL9, CCL11, SLAMF1, CXCL11 and MCP-1) were up-regulated (P < .05) in preclinical ulcerative colitis compared with controls based on both univariate and multivariable models. Ingenuity Pathway Analyses identified several potential key regulators, including interleukin-1β, tumor necrosis factor, interferon-gamma, oncostatin M, nuclear factor-κB, interleukin-6, and interleukin-4. For validation, we built a multivariable model to predict disease in the inception cohort. The model discriminated treatment-naïve patients with ulcerative colitis from controls with leave-one-out cross-validation (area under the curve = 0.92). Consistently, MMP10, CXCL9, CXCL11, and MCP-1, but not CCL11 and SLAMF1, were significantly up-regulated among the healthy twin siblings, even though their relative abundances seemed higher in incident ulcerative colitis.

Conclusions: A set of inflammatory proteins are up-regulated several years before a diagnosis of ulcerative colitis. These proteins were highly predictive of an ulcerative colitis diagnosis, and some seemed to be up-regulated already at exposure to genetic and environmental risk factors.

Keywords: CXCL9; Inflammatory Bowel Disease; MMP10; Preclinical Disease; Proximity Extension Assay.

Publication types

  • Research Support, Non-U.S. Gov't
  • Twin Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • Blood Proteins / analysis*
  • Case-Control Studies
  • Chemokine CCL11 / blood
  • Chemokine CCL2 / blood
  • Chemokine CXCL11 / blood
  • Chemokine CXCL9 / blood
  • Colitis, Ulcerative / blood*
  • Colitis, Ulcerative / diagnosis
  • Colitis, Ulcerative / immunology
  • Female
  • Humans
  • Inflammation Mediators / blood*
  • Male
  • Matrix Metalloproteinase 10 / blood
  • Middle Aged
  • Predictive Value of Tests
  • Proteome*
  • Proteomics
  • Reproducibility of Results
  • Signaling Lymphocytic Activation Molecule Family Member 1 / blood
  • Up-Regulation
  • Young Adult

Substances

  • Biomarkers
  • Blood Proteins
  • CCL11 protein, human
  • CCL2 protein, human
  • CXCL11 protein, human
  • CXCL9 protein, human
  • Chemokine CCL11
  • Chemokine CCL2
  • Chemokine CXCL11
  • Chemokine CXCL9
  • Inflammation Mediators
  • Proteome
  • SLAMF1 protein, human
  • Signaling Lymphocytic Activation Molecule Family Member 1
  • MMP10 protein, human
  • Matrix Metalloproteinase 10